STOCK TITAN

[Form 4] Neuropace, Inc. Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
4
Rhea-AI Filing Summary

NeuroPace director Frank M. Fischer reported multiple acquisitions of common stock through the company's non-employee director compensation policy in lieu of quarterly retainer fees from June 2023 to June 2025. Key transactions include:

  • Most recent acquisition: 2,281 shares at $10.41 per share on June 21, 2025
  • Largest acquisition: 4,469 shares at $4.49 per share on June 30, 2023
  • Total shares accumulated: Increased position from 570,126 to 589,531 shares
  • Share price range: $4.49 to $13.20 across nine quarterly acquisitions

All transactions were direct ownership acquisitions, with no derivative securities involved. The consistent pattern of stock acquisitions in lieu of cash compensation demonstrates the director's long-term alignment with shareholder interests and confidence in the company's future.

Il direttore di NeuroPace, Frank M. Fischer, ha segnalato numerosi acquisti di azioni ordinarie tramite la politica di compensazione per i direttori non dipendenti della società, in sostituzione delle commissioni trimestrali, da giugno 2023 a giugno 2025. Le operazioni principali includono:

  • Acquisto più recente: 2.281 azioni a 10,41$ per azione il 21 giugno 2025
  • Acquisto più consistente: 4.469 azioni a 4,49$ per azione il 30 giugno 2023
  • Totale azioni accumulate: posizione aumentata da 570.126 a 589.531 azioni
  • Fascia di prezzo delle azioni: da 4,49$ a 13,20$ in nove acquisti trimestrali

Tutte le transazioni hanno riguardato acquisizioni dirette di proprietà, senza strumenti derivati coinvolti. Il costante schema di acquisti azionari in sostituzione della compensazione in contanti dimostra l’allineamento a lungo termine del direttore con gli interessi degli azionisti e la fiducia nel futuro dell’azienda.

El director de NeuroPace, Frank M. Fischer, informó múltiples adquisiciones de acciones ordinarias a través de la política de compensación para directores no empleados de la empresa, en lugar de honorarios trimestrales, desde junio de 2023 hasta junio de 2025. Las transacciones clave incluyen:

  • Adquisición más reciente: 2.281 acciones a 10,41$ por acción el 21 de junio de 2025
  • Adquisición más grande: 4.469 acciones a 4,49$ por acción el 30 de junio de 2023
  • Total de acciones acumuladas: aumento de la posición de 570.126 a 589.531 acciones
  • Rango de precio por acción: de 4,49$ a 13,20$ en nueve adquisiciones trimestrales

Todas las transacciones fueron adquisiciones de propiedad directa, sin involucrar valores derivados. El patrón constante de compras de acciones en lugar de compensación en efectivo demuestra la alineación a largo plazo del director con los intereses de los accionistas y la confianza en el futuro de la compañía.

NeuroPace 이사 Frank M. Fischer는 2023년 6월부터 2025년 6월까지 분기별 보수 대신 회사의 비임원 이사 보상 정책을 통해 보통주를 여러 차례 매입했다고 보고했습니다. 주요 거래 내역은 다음과 같습니다:

  • 가장 최근 매입: 2025년 6월 21일 주당 10.41달러에 2,281주 매입
  • 가장 큰 매입: 2023년 6월 30일 주당 4.49달러에 4,469주 매입
  • 총 주식 보유량: 570,126주에서 589,531주로 증가
  • 주가 범위: 9번의 분기별 매입에서 주당 4.49달러에서 13.20달러 사이

모든 거래는 파생상품 없이 직접 주식 소유권 취득으로 이루어졌습니다. 현금 보상 대신 주식 매입을 꾸준히 이어가는 것은 이사가 주주 이익과 회사의 미래에 장기적으로 일치하는 신뢰를 보여줍니다.

Le directeur de NeuroPace, Frank M. Fischer, a déclaré plusieurs acquisitions d’actions ordinaires dans le cadre de la politique de rémunération des administrateurs non salariés de la société, en lieu et place des honoraires trimestriels, de juin 2023 à juin 2025. Les transactions clés comprennent :

  • Acquisition la plus récente : 2 281 actions à 10,41 $ par action le 21 juin 2025
  • Acquisition la plus importante : 4 469 actions à 4,49 $ par action le 30 juin 2023
  • Total des actions accumulées : position augmentée de 570 126 à 589 531 actions
  • Fourchette de prix des actions : de 4,49 $ à 13,20 $ sur neuf acquisitions trimestrielles

Toutes les transactions étaient des acquisitions directes de propriété, sans recours à des instruments dérivés. Le schéma constant d’achats d’actions en lieu et place d’une rémunération en espèces démontre l’alignement à long terme du directeur avec les intérêts des actionnaires et sa confiance dans l’avenir de la société.

Der NeuroPace-Direktor Frank M. Fischer meldete mehrere Erwerbe von Stammaktien im Rahmen der Vergütungspolitik für nicht angestellte Direktoren des Unternehmens anstelle von vierteljährlichen Pauschalvergütungen von Juni 2023 bis Juni 2025. Wichtige Transaktionen umfassen:

  • Neuester Erwerb: 2.281 Aktien zu je 10,41 $ am 21. Juni 2025
  • Größter Erwerb: 4.469 Aktien zu je 4,49 $ am 30. Juni 2023
  • Gesamtzahl der angehäuften Aktien: Position von 570.126 auf 589.531 Aktien erhöht
  • Aktienkursbereich: 4,49 $ bis 13,20 $ über neun vierteljährliche Erwerbe

Alle Transaktionen waren direkte Eigentumserwerbe ohne Beteiligung von Derivaten. Das konsequente Muster von Aktienkäufen anstelle von Barvergütung zeigt die langfristige Ausrichtung des Direktors auf die Interessen der Aktionäre und sein Vertrauen in die Zukunft des Unternehmens.

Positive
  • None.
Negative
  • None.

Il direttore di NeuroPace, Frank M. Fischer, ha segnalato numerosi acquisti di azioni ordinarie tramite la politica di compensazione per i direttori non dipendenti della società, in sostituzione delle commissioni trimestrali, da giugno 2023 a giugno 2025. Le operazioni principali includono:

  • Acquisto più recente: 2.281 azioni a 10,41$ per azione il 21 giugno 2025
  • Acquisto più consistente: 4.469 azioni a 4,49$ per azione il 30 giugno 2023
  • Totale azioni accumulate: posizione aumentata da 570.126 a 589.531 azioni
  • Fascia di prezzo delle azioni: da 4,49$ a 13,20$ in nove acquisti trimestrali

Tutte le transazioni hanno riguardato acquisizioni dirette di proprietà, senza strumenti derivati coinvolti. Il costante schema di acquisti azionari in sostituzione della compensazione in contanti dimostra l’allineamento a lungo termine del direttore con gli interessi degli azionisti e la fiducia nel futuro dell’azienda.

El director de NeuroPace, Frank M. Fischer, informó múltiples adquisiciones de acciones ordinarias a través de la política de compensación para directores no empleados de la empresa, en lugar de honorarios trimestrales, desde junio de 2023 hasta junio de 2025. Las transacciones clave incluyen:

  • Adquisición más reciente: 2.281 acciones a 10,41$ por acción el 21 de junio de 2025
  • Adquisición más grande: 4.469 acciones a 4,49$ por acción el 30 de junio de 2023
  • Total de acciones acumuladas: aumento de la posición de 570.126 a 589.531 acciones
  • Rango de precio por acción: de 4,49$ a 13,20$ en nueve adquisiciones trimestrales

Todas las transacciones fueron adquisiciones de propiedad directa, sin involucrar valores derivados. El patrón constante de compras de acciones en lugar de compensación en efectivo demuestra la alineación a largo plazo del director con los intereses de los accionistas y la confianza en el futuro de la compañía.

NeuroPace 이사 Frank M. Fischer는 2023년 6월부터 2025년 6월까지 분기별 보수 대신 회사의 비임원 이사 보상 정책을 통해 보통주를 여러 차례 매입했다고 보고했습니다. 주요 거래 내역은 다음과 같습니다:

  • 가장 최근 매입: 2025년 6월 21일 주당 10.41달러에 2,281주 매입
  • 가장 큰 매입: 2023년 6월 30일 주당 4.49달러에 4,469주 매입
  • 총 주식 보유량: 570,126주에서 589,531주로 증가
  • 주가 범위: 9번의 분기별 매입에서 주당 4.49달러에서 13.20달러 사이

모든 거래는 파생상품 없이 직접 주식 소유권 취득으로 이루어졌습니다. 현금 보상 대신 주식 매입을 꾸준히 이어가는 것은 이사가 주주 이익과 회사의 미래에 장기적으로 일치하는 신뢰를 보여줍니다.

Le directeur de NeuroPace, Frank M. Fischer, a déclaré plusieurs acquisitions d’actions ordinaires dans le cadre de la politique de rémunération des administrateurs non salariés de la société, en lieu et place des honoraires trimestriels, de juin 2023 à juin 2025. Les transactions clés comprennent :

  • Acquisition la plus récente : 2 281 actions à 10,41 $ par action le 21 juin 2025
  • Acquisition la plus importante : 4 469 actions à 4,49 $ par action le 30 juin 2023
  • Total des actions accumulées : position augmentée de 570 126 à 589 531 actions
  • Fourchette de prix des actions : de 4,49 $ à 13,20 $ sur neuf acquisitions trimestrielles

Toutes les transactions étaient des acquisitions directes de propriété, sans recours à des instruments dérivés. Le schéma constant d’achats d’actions en lieu et place d’une rémunération en espèces démontre l’alignement à long terme du directeur avec les intérêts des actionnaires et sa confiance dans l’avenir de la société.

Der NeuroPace-Direktor Frank M. Fischer meldete mehrere Erwerbe von Stammaktien im Rahmen der Vergütungspolitik für nicht angestellte Direktoren des Unternehmens anstelle von vierteljährlichen Pauschalvergütungen von Juni 2023 bis Juni 2025. Wichtige Transaktionen umfassen:

  • Neuester Erwerb: 2.281 Aktien zu je 10,41 $ am 21. Juni 2025
  • Größter Erwerb: 4.469 Aktien zu je 4,49 $ am 30. Juni 2023
  • Gesamtzahl der angehäuften Aktien: Position von 570.126 auf 589.531 Aktien erhöht
  • Aktienkursbereich: 4,49 $ bis 13,20 $ über neun vierteljährliche Erwerbe

Alle Transaktionen waren direkte Eigentumserwerbe ohne Beteiligung von Derivaten. Das konsequente Muster von Aktienkäufen anstelle von Barvergütung zeigt die langfristige Ausrichtung des Direktors auf die Interessen der Aktionäre und sein Vertrauen in die Zukunft des Unternehmens.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Fischer Frank M

(Last) (First) (Middle)
C/O NEUROPACE, INC.
455 N. BERNARDO AVENUE

(Street)
MOUNTAIN VIEW CA 94043

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
NeuroPace Inc [ NPCE ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
06/30/2023
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 06/30/2023 A 4,469(1) A $4.49 570,126 D
Common Stock 09/29/2023 A 2,440(1) A $9.73 572,566 D
Common Stock 12/29/2023 A 2,303(1) A $10.31 574,869 D
Common Stock 03/29/2024 A 1,799(1) A $13.2 576,668 D
Common Stock 06/28/2024 A 3,141(1) A $7.56 579,809 D
Common Stock 09/30/2024 A 3,407(1) A $6.97 583,216 D
Common Stock 12/21/2024 A 2,059(1) A $11.53 585,275 D
Common Stock 03/21/2025 A 1,975(1) A $12.02 587,250 D
Common Stock 06/21/2025 A 2,281(1) A $10.41 589,531 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. These shares were issued to the Reporting Person pursuant to the Issuer's non-employee director compensation policy in lieu of quarterly retainer fees.
/s/ Leah Akin, Attorney-in-Fact 06/24/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many NPCE shares did Director Frank Fischer acquire in June 2025?

According to the Form 4 filing, Director Frank Fischer acquired 2,281 shares of NPCE common stock on June 21, 2025, at a price of $10.41 per share.

What is the total number of NPCE shares Frank Fischer owns after his latest transaction?

Following the most recent transaction on June 21, 2025, Frank Fischer beneficially owns 589,531 shares of NPCE common stock directly.

Why did Frank Fischer receive NPCE shares throughout 2023-2025?

According to the filing's explanation of responses, the shares were issued to Fischer pursuant to NeuroPace's non-employee director compensation policy in lieu of quarterly retainer fees.

What was the highest price per share NPCE paid for Director Fischer's compensation in 2023-2025?

The highest price per share among the reported transactions was $13.20, which occurred on March 29, 2024, when Fischer received 1,799 shares.

Does Frank Fischer own any derivative securities of NPCE?

No, according to Table II of the Form 4 filing, Frank Fischer does not hold any derivative securities such as stock options, warrants, or convertible securities of NPCE.
Neuropace Inc

NASDAQ:NPCE

NPCE Rankings

NPCE Latest News

NPCE Latest SEC Filings

NPCE Stock Data

346.68M
24.06M
3.38%
61.73%
0.75%
Medical Devices
Surgical & Medical Instruments & Apparatus
Link
United States
MOUNTAIN VIEW